Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Uptravi® (SelexiPag): tHe usErs dRug rEgistry

Trial Profile

Uptravi® (SelexiPag): tHe usErs dRug rEgistry

Phase of Trial: Phase IV

Latest Information Update: 21 Sep 2018

At a glance

  • Drugs Selexipag (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SPHERE
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 06 Jul 2018 Planned number of patients changed from 500 to 800.
    • 06 Jul 2018 Planned End Date changed from 30 Jun 2020 to 30 Jun 2022.
    • 06 Jul 2018 Planned primary completion date changed from 30 Jun 2020 to 30 Jun 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top